Shares in Ionis Pharmaceuticals (Nasdaq: IONS) have plunged 40% after GlaxoSmithKline (LSE: GSK) scrapped plans to test the company’s IONIS-TTR heart drug in late-stage trials.
The decision is a serious blow to the California-based company which saw more than $900 million wiped from its market value as a result. It comes two months after the US Food and Drug Administration put a clinical hold on the trial testing the drug, citing safety concerns.
IONIS-TTR is being developed for the treatment of transthyretin cardiomyopathy, a rare and fatal disease associated with progressive heart failure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze